| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | paclitaxel | FIMM | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |